Clinical trials / NCT05352893
NCT05352893Phase 3Completed

Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP

Study sponsor: Vanda Pharmaceuticals

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov recordCSV export · Pro
Primary completion2023-08-17Actual
Enrollment · participants45Actual
Source updated2026-03-17Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 1 field changed

Primary outcomes · main study measures

Text edit · unverified significance
− Previous value

measure: Proportion of Patients Achieving a GPPPGA Score of 0 (Clear) or 1 (Almost Clear)

+ Updated value

measure: Percentage of Patients Achieving a GPPPGA Score of 0 (Clear) or 1 (Almost Clear)

The saved outcome text may be shortened. Check the source for full wording.

Check registry source

· 1 field changed

Primary outcomes · main study measures

Text edit · unverified significance
− Previous value

measure: Proportion of subjects achieving Generalized Pustular Psoriasis Physician's Global Assessment (GPPPGA) score of 0 (clear) or 1 (almost clear)

+ Updated value

measure: Proportion of Patients Achieving a GPPPGA Score of 0 (Clear) or 1 (Almost Clear)

The saved outcome text may be shortened. Check the source for full wording.

Check registry source